



Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-748F	Not Yet Assigned
	Applicant Armistead et al.	
	Filing Date	Group
	October 31, 2003	1624

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS		INVENTION NUMBER	DATE	COUNTRY	CLASS	CIP. CLASS	TRANSLATION	
							YES	NO
VB	B1	CH 261,812	9/1/49	SWITZERLAND				X
VB	B2	EP 0 002 341	06/13/79	EP			X	
VB	B3	EP 0 379 806 B1	8/1/90	EP			X	
VB	B4	EP 0 945 443	09/29/99	EP			X	
VB	B5	EP 1 040 831 A2	4/10/00	EP			X	
VB	B6	GB 1,390,235	4/9/75	GREAT BRITAIN			X	
VB	B7	WO 94/26733	11/24/94	PCT			X	
VB	B8	WO 95/33750	12/14/95	PCT			X	
VB	B9	WO 96/05177	02/22/96	PCT			X	
VB	B10	WO 97/19065	05/29/97	PCT			X	
VB	B11	WO 98/18782	05/07/98	PCT			X	
VB	B12	WO 99/01136	1/14/99	PCT			X	
VB	B13	WO 99/31073	6/24/99	PCT				X
VB	B14	WO 99/31121	6/24/99	PCT			X	
VB	B15	WO 99/41253	8/19/99	PCT			X	
VB	B16	WO 99/50250	10/7/99	PCT			X	
VB	B17	WO 99/65909	12/23/99	PCT			X	
VB	B18	WO 00/12485	3/9/00	PCT			X	
VB	B19	WO 00/27825	5/18/00	PCT			X	
VB	B20	WO 00/39101	7/6/00	PCT			X	
VB	B21	WO 00/43373	7/27/00	PCT			X	

EXAMINER: <u>V. Balasubramanian</u>	Date Considered: <u>6/28/04</u>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-748F	Not Yet Assigned
	Applicant	
	Armistead et al.	
	Filing Date	Group
	October 31, 2003	1624

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CITE CLASS	TRANSLATION	
							YES	NO
M	B22	WO 00/53595	09/14/00	PCT			X	
M	B23	WO 00/59892	10/12/00	PCT			X	
M	B24	WO 00/63204	10/26/00	PCT			X	
M	B25	WO 00/78731	12/28/00	PCT			X	
M	B26	WO 01/00213	01/4/01	PCT			X	
M	B27	WO 01/22938	4/5/01	PCT			X	
M	B28	WO 01/29009	4/26/01	PCT			X	
M	B29	WO 01/40218	6/7/01	PCT				X

EXAMINER'S INITIALS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

M	C1	Shapiro, et al., <i>Guanamine Diuretics</i> , Journal of the American Chemical Society, American Chemical Society, Washington DC, US, XP-002110860, Vol. 79, 5064-5071 (1957)
M	C2	Arteaga et al. " <i>HER (erbB) Tyrosine Kinase Inhibitors in the Treatment of Breast Cancer</i> " Seminars in Oncology 29(No. 2 Suppl. 11) 4-10 (2002).
M	C3	Bolen et al., " <i>Leukocyte Protein Tyrosine Kinases: Potential Targets for Drug Discovery</i> " Annu. Rev. Immunology 15: 371-404 (1997)
M	C4	Gao et al., " <i>Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models</i> " PNAS (Proceedings of the National Academy of Sciences of the United States of America) 98:13 7443-7448.
M	C5	Khandwala et al. " <i>The effects of Insulin-like growth factors on Tumorigenesis and Neoplastic Growth</i> " Endocrine Reviews 21(3): 215-244 (2000)
M	C6	Muller et al., " <i>Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia</i> " Leukemia Research 26:163-168 (2002)
ay	C7	Raymond et al., " <i>Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy</i> " Drugs 60 Suppl.1: 15-23 (2000)
ay	C8	Scheijen et al. " <i>Tyrosine kinase oncogenes in normal hematopoiesis and hemtological disease</i> " Oncogene 21: 3314-3333 (2002)
M	C9	Sweeney et al., " <i>Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor</i> " Kidney International, 57: 33-40 (2000)

EXAMINER:

V Balasubramanian

Date Considered:

6/28/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.